Sinkule J A, Evans W E
J Pharm Sci. 1984 Feb;73(2):164-8. doi: 10.1002/jps.2600730207.
A high-performance liquid chromatographic (HPLC) assay was developed for the quantitation of two structurally similar and highly active anticancer drugs, etoposide (I) and teniposide (II), and their potential metabolites (hydroxy acid, picrolactone, and aglycone). The assay utilizes electrochemical detection, which imparts specificity and sensitivity sufficient to detect greater than or equal to 20 ng/mL in plasma, urine, and CSF. The mean assay coefficients of variation were 5.1 and 8.1% for teniposide (10 micrograms/mL) and etoposide (5 micrograms/mL), respectively. The extraction efficiencies were 86% for etoposide, 70% for its hydroxy acid metabolite, 66% for teniposide, and 54% for the hydroxy acid of teniposide. The correlation coefficient of the multilevel standard curve was greater than or equal to 0.995 over the concentration range of 0.05-50 micrograms/mL for the parent drugs and metabolites extracted from plasma. This method has been used to determine the concentrations of the parent drugs and their metabolites in the plasma, urine, and CSF of patients with cancer.
开发了一种高效液相色谱(HPLC)分析法,用于定量测定两种结构相似且具有高活性的抗癌药物依托泊苷(I)和替尼泊苷(II)及其潜在代谢物(羟基酸、苦内酯和苷元)。该分析法采用电化学检测,具有足够的特异性和灵敏度,能够检测血浆、尿液和脑脊液中大于或等于20 ng/mL的药物。替尼泊苷(10微克/毫升)和依托泊苷(5微克/毫升)的分析变异系数平均值分别为5.1%和8.1%。依托泊苷的提取效率为86%,其羟基酸代谢物的提取效率为70%,替尼泊苷的提取效率为66%,替尼泊苷羟基酸的提取效率为54%。对于从血浆中提取的母体药物和代谢物,在0.05 - 50微克/毫升的浓度范围内,多级标准曲线的相关系数大于或等于0.995。该方法已用于测定癌症患者血浆、尿液和脑脊液中母体药物及其代谢物的浓度。